Virax Biolabs announces extraordinary shareholder meeting

• Virax Biolabs has called an extraordinary general meeting in Glasgow on June 5, 2026.
• Shareholders will vote on a proposed consolidation of the company’s ordinary shares at a ratio to be set by the board within a 10-for-1 to 30-for-1 range, with fractional entitlements to be rounded up.
• The meeting will also consider adopting an amended and restated memorandum and articles of association to reflect the share consolidation.
• A separate proposal seeks approval to adjourn the meeting if needed to secure enough votes on the items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-236980), on May 22, 2026, and is solely responsible for the information contained therein.